A study cohort that received an oral supplement of a gut-produced compound had better endurance in two small exercises.

An oral supplement intended to stimulate a natural body process appears to promote muscle endurance and mitochondrial health in humans. New research suggests that the supplement, urolithin A, may help improve or prolong muscle activity in people who are aging or who have diseases that make exercise difficult.

The paper was published in JAMA Network Open.

“Altos Labs is just the latest in a series of anti-aging research institutes to emerge recently. With so much money being poured into the science of living longer, there is reason to be optimistic for those hoping to reach longevity escape velocity.”

https://www.futuretimeline.net/images/backgrounds/join-our-f…ground.jpg #longevity

Altos Labs, a new biotech startup focused on deep biology of cellular rejuvenation programming, has been launched with $3bn in funding.

For it is they who are leading a charge towards a new frontier in medicine that will revolutionise our ‘healthspans’ — the number of years of good health we can expect to enjoy — and push back the worst effects of ageing.

The announcement this week that a new anti-ageing company, Altos Labs, which is based in the U.S. and UK, has been established to ‘hack’ the ageing process has reignited interest in the science of rejuvenation, an obsession that has spanned continents and the ages.

https://www.google.com/amp/s/amp.ft.com/content/2b869472&#45…28788e8dd4

“GlaxoSmithKline’s chief scientific officer Hal Barron will step down in August as he moves to lead a Silicon Valley anti-ageing start-up, dealing a blow to the pharma group as it races to rebuild its pipeline of drugs.”

Link: Big Pharma loses top scientist to anti-aging research.

GlaxoSmithKline’s chief scientific officer Hal Barron will step down in August as he moves to lead a Silicon Valley anti-ageing start-up, dealing a blow to the pharma group as it races to rebuild its pipeline of drugs.

Hal Barron, a veteran drug developer, helped shape GSK efforts when some shareholders raised concerns that chief executive Emma Walmsley’s lack of a scientific background was a hindrance. He will be replaced by internal candidate Tony Wood.

Barron is leaving GSK to take up the top job at Altos Labs, a start-up reportedly backed by billionaires including Amazon founder Jeff Bezos. He will remain on GSK’s board as a non-executive director and continue to provide scientific advice.